Boston Scientific Q4 Beats, But Stent Sales Weak

By | February 4, 2014

Scalper1 News

Medical-device giant Boston Scientific (BSX) beat analysts’ Q4 profit estimates Tuesday, but shares fell on the stock market today as analysts spotted weaknesses in other aspects of the report. The company said profit rose 17% over the year-earlier quarter to 21 cents a share, beating analysts’ consensus by 8 cents, according to Thomson Reuters. Sales rose 1% to $1.84 billion, slightly ahead of consensus. Boston Sci also offered 2014 guidance for Scalper1 News

Scalper1 News